Celgene has agreed to pay Epizyme US$90 M upfront, including an equity investment, as part of a deal to discover, develop and commercialise histone methyltransferase (HMT) inhibitors for patients with genetically defined cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd